#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Over the last two decades , remarkable progress has been made in understanding the etiology and pathophysiology of diseases .
1-1	0-4	Over	_	_	_	_
1-2	5-8	the	time[1]	new[1]	_	_
1-3	9-13	last	time[1]	new[1]	_	_
1-4	14-17	two	time[1]	new[1]	_	_
1-5	18-25	decades	time[1]	new[1]	_	_
1-6	26-27	,	_	_	_	_
1-7	28-38	remarkable	abstract[2]	new[2]	_	_
1-8	39-47	progress	abstract[2]	new[2]	_	_
1-9	48-51	has	_	_	_	_
1-10	52-56	been	_	_	_	_
1-11	57-61	made	_	_	_	_
1-12	62-64	in	_	_	_	_
1-13	65-78	understanding	_	_	_	_
1-14	79-82	the	abstract[3]	new[3]	_	_
1-15	83-91	etiology	abstract[3]	new[3]	_	_
1-16	92-95	and	_	_	_	_
1-17	96-111	pathophysiology	abstract[4]	new[4]	_	_
1-18	112-114	of	abstract[4]	new[4]	_	_
1-19	115-123	diseases	abstract[4]|abstract	new[4]|new	coref	3-38[22_0]
1-20	124-125	.	_	_	_	_

#Text=New discoveries emphasize the importance of the small bowel ( SB ) ‘ ecosystem ’ in the pathogenesis of acute and chronic illness alike .
2-1	126-129	New	abstract[6]	new[6]	coref	5-1[31_6]
2-2	130-141	discoveries	abstract[6]	new[6]	_	_
2-3	142-151	emphasize	_	_	_	_
2-4	152-155	the	abstract[7]	new[7]	_	_
2-5	156-166	importance	abstract[7]	new[7]	_	_
2-6	167-169	of	abstract[7]	new[7]	_	_
2-7	170-173	the	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-8	174-179	small	abstract[7]|object[8]|abstract[10]	new[7]|new[8]|new[10]	coref	20-12[0_8]
2-9	180-185	bowel	abstract[7]|object[8]|abstract[10]	new[7]|new[8]|new[10]	_	_
2-10	186-187	(	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-11	188-190	SB	abstract[7]|abstract|abstract[10]	new[7]|new|new[10]	coref	6-11[41_0]
2-12	191-192	)	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-13	193-194	‘	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-14	195-204	ecosystem	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-15	205-206	’	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-16	207-209	in	abstract[7]	new[7]	_	_
2-17	210-213	the	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-18	214-226	pathogenesis	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-19	227-229	of	abstract[7]|abstract[11]	new[7]|new[11]	_	_
2-20	230-235	acute	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-21	236-239	and	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-22	240-247	chronic	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-23	248-255	illness	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-24	256-261	alike	abstract[7]|abstract[11]|abstract[12]	new[7]|new[11]|new[12]	_	_
2-25	262-263	.	_	_	_	_

#Text=Emerging factors , such as microbiome , stem and progenitor cells , innate intestinal immunity , and the enteric nervous system , along with mucosal and endothelial barriers , play a key role in the development of gastrointestinal ( GI ) and extra-GI diseases .
3-1	264-272	Emerging	abstract[13]	new[13]	_	_
3-2	273-280	factors	abstract[13]	new[13]	_	_
3-3	281-282	,	abstract[13]	new[13]	_	_
3-4	283-287	such	abstract[13]	new[13]	_	_
3-5	288-290	as	abstract[13]	new[13]	_	_
3-6	291-301	microbiome	abstract[13]|abstract	new[13]|new	_	_
3-7	302-303	,	abstract[13]	new[13]	_	_
3-8	304-308	stem	abstract[13]|place[16]	new[13]|new[16]	coref	11-9[83_16]
3-9	309-312	and	abstract[13]|place[16]	new[13]|new[16]	_	_
3-10	313-323	progenitor	abstract[13]|object|place[16]	new[13]|new|new[16]	_	_
3-11	324-329	cells	abstract[13]|place[16]	new[13]|new[16]	_	_
3-12	330-331	,	abstract[13]	new[13]	_	_
3-13	332-338	innate	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-14	339-349	intestinal	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-15	350-358	immunity	abstract[13]|abstract[17]	new[13]|new[17]	_	_
3-16	359-360	,	abstract[13]	new[13]	_	_
3-17	361-364	and	abstract[13]	new[13]	_	_
3-18	365-368	the	abstract[13]|abstract[18]	new[13]|new[18]	coref	13-6[105_18]
3-19	369-376	enteric	abstract[13]|abstract[18]	new[13]|new[18]	_	_
3-20	377-384	nervous	abstract[13]|abstract[18]	new[13]|new[18]	_	_
3-21	385-391	system	abstract[13]|abstract[18]	new[13]|new[18]	_	_
3-22	392-393	,	_	_	_	_
3-23	394-399	along	_	_	_	_
3-24	400-404	with	_	_	_	_
3-25	405-412	mucosal	object[19]	new[19]	_	_
3-26	413-416	and	object[19]	new[19]	_	_
3-27	417-428	endothelial	object[19]	new[19]	_	_
3-28	429-437	barriers	object[19]	new[19]	_	_
3-29	438-439	,	_	_	_	_
3-30	440-444	play	_	_	_	_
3-31	445-446	a	abstract[20]	new[20]	coref	6-4[39_20]
3-32	447-450	key	abstract[20]	new[20]	_	_
3-33	451-455	role	abstract[20]	new[20]	_	_
3-34	456-458	in	abstract[20]	new[20]	_	_
3-35	459-462	the	abstract[20]|event[21]	new[20]|new[21]	_	_
3-36	463-474	development	abstract[20]|event[21]	new[20]|new[21]	_	_
3-37	475-477	of	abstract[20]|event[21]	new[20]|new[21]	_	_
3-38	478-494	gastrointestinal	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	coref	4-16[28_22]
3-39	495-496	(	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-40	497-499	GI	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-41	500-501	)	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-42	502-505	and	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-43	506-514	extra-GI	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-44	515-523	diseases	abstract[20]|event[21]|abstract[22]	new[20]|new[21]|giv[22]	_	_
3-45	524-525	.	_	_	_	_

#Text=The results of other studies point also towards a link between the digestive tract and common non-communicable diseases , such as obesity and cancer .
4-1	526-529	The	abstract[23]	new[23]	_	_
4-2	530-537	results	abstract[23]	new[23]	_	_
4-3	538-540	of	abstract[23]	new[23]	_	_
4-4	541-546	other	abstract[23]|abstract[24]	new[23]|new[24]	coref	6-1[38_24]
4-5	547-554	studies	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-6	555-560	point	_	_	_	_
4-7	561-565	also	_	_	_	_
4-8	566-573	towards	_	_	_	_
4-9	574-575	a	abstract[25]	new[25]	_	_
4-10	576-580	link	abstract[25]	new[25]	_	_
4-11	581-588	between	abstract[25]	new[25]	_	_
4-12	589-592	the	abstract[25]|object[26]|object[27]	new[25]|new[26]|new[27]	coref|coref	13-1[103_26]|13-1[104_27]
4-13	593-602	digestive	abstract[25]|object[26]|object[27]	new[25]|new[26]|new[27]	_	_
4-14	603-608	tract	abstract[25]|object[26]|object[27]	new[25]|new[26]|new[27]	_	_
4-15	609-612	and	abstract[25]|object[27]	new[25]|new[27]	_	_
4-16	613-619	common	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	coref	19-22[159_28]
4-17	620-636	non-communicable	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-18	637-645	diseases	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-19	646-647	,	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-20	648-652	such	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-21	653-655	as	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-22	656-663	obesity	abstract[25]|object[27]|abstract[28]|abstract	new[25]|new[27]|giv[28]|new	coref	7-20
4-23	664-667	and	abstract[25]|object[27]|abstract[28]	new[25]|new[27]|giv[28]	_	_
4-24	668-674	cancer	abstract[25]|object[27]|abstract[28]|abstract	new[25]|new[27]|giv[28]|new	_	_
4-25	675-676	.	_	_	_	_

#Text=These discoveries unravel novel dimensions of uncertainty in the area of clinical decision-making motivating researchers to search for novel diagnostic and therapeutic solutions .
5-1	677-682	These	abstract[31]	giv[31]	_	_
5-2	683-694	discoveries	abstract[31]	giv[31]	_	_
5-3	695-702	unravel	_	_	_	_
5-4	703-708	novel	abstract[32]	new[32]	_	_
5-5	709-719	dimensions	abstract[32]	new[32]	_	_
5-6	720-722	of	abstract[32]	new[32]	_	_
5-7	723-734	uncertainty	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-8	735-737	in	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-9	738-741	the	abstract[32]|abstract[33]|abstract[34]	new[32]|new[33]|new[34]	_	_
5-10	742-746	area	abstract[32]|abstract[33]|abstract[34]	new[32]|new[33]|new[34]	_	_
5-11	747-749	of	abstract[32]|abstract[33]|abstract[34]	new[32]|new[33]|new[34]	_	_
5-12	750-758	clinical	abstract[32]|abstract[33]|abstract[34]|abstract[35]	new[32]|new[33]|new[34]|new[35]	_	_
5-13	759-774	decision-making	abstract[32]|abstract[33]|abstract[34]|abstract[35]	new[32]|new[33]|new[34]|new[35]	_	_
5-14	775-785	motivating	_	_	_	_
5-15	786-797	researchers	person	new	_	_
5-16	798-800	to	_	_	_	_
5-17	801-807	search	_	_	_	_
5-18	808-811	for	_	_	_	_
5-19	812-817	novel	abstract[37]	new[37]	_	_
5-20	818-828	diagnostic	abstract[37]	new[37]	_	_
5-21	829-832	and	abstract[37]	new[37]	_	_
5-22	833-844	therapeutic	abstract[37]	new[37]	_	_
5-23	845-854	solutions	abstract[37]	new[37]	_	_
5-24	855-856	.	_	_	_	_

#Text=Recent studies unravel the role of the poorly-understood complexity of the SB .
6-1	857-863	Recent	abstract[38]	giv[38]	_	_
6-2	864-871	studies	abstract[38]	giv[38]	_	_
6-3	872-879	unravel	_	_	_	_
6-4	880-883	the	abstract[39]	giv[39]	coref	7-3[44_39]
6-5	884-888	role	abstract[39]	giv[39]	_	_
6-6	889-891	of	abstract[39]	giv[39]	_	_
6-7	892-895	the	abstract[39]|substance[40]	giv[39]|new[40]	ana	7-3[0_40]
6-8	896-913	poorly-understood	abstract[39]|substance[40]	giv[39]|new[40]	_	_
6-9	914-924	complexity	abstract[39]|substance[40]	giv[39]|new[40]	_	_
6-10	925-927	of	abstract[39]|substance[40]	giv[39]|new[40]	_	_
6-11	928-931	the	abstract[39]|substance[40]|abstract[41]	giv[39]|new[40]|giv[41]	coref	11-9[0_41]
6-12	932-934	SB	abstract[39]|substance[40]|abstract[41]	giv[39]|new[40]|giv[41]	_	_
6-13	935-936	.	_	_	_	_

#Text=Insights into its critical physiologic and pathophysiologic role in metabolic homeostasis and its potential role as a driver of obesity , insulin resistance , and subsequent type 2 diabetes mellitus ( T2DM ) have been revealed .
7-1	937-945	Insights	abstract[42]	new[42]	_	_
7-2	946-950	into	abstract[42]	new[42]	_	_
7-3	951-954	its	abstract[42]|substance|abstract[44]	new[42]|giv|giv[44]	ana|coref	7-13|7-13[47_44]
7-4	955-963	critical	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-5	964-975	physiologic	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-6	976-979	and	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-7	980-996	pathophysiologic	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-8	997-1001	role	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-9	1002-1004	in	abstract[42]|abstract[44]	new[42]|giv[44]	_	_
7-10	1005-1014	metabolic	abstract[42]|abstract[44]|abstract[45]	new[42]|giv[44]|new[45]	coref	9-24[68_45]
7-11	1015-1026	homeostasis	abstract[42]|abstract[44]|abstract[45]	new[42]|giv[44]|new[45]	_	_
7-12	1027-1030	and	abstract[42]	new[42]	_	_
7-13	1031-1034	its	abstract[42]|substance|abstract[47]	new[42]|giv|giv[47]	coref	19-15[157_47]
7-14	1035-1044	potential	abstract[42]|abstract[47]	new[42]|giv[47]	_	_
7-15	1045-1049	role	abstract[42]|abstract[47]	new[42]|giv[47]	_	_
7-16	1050-1052	as	abstract[42]|abstract[47]	new[42]|giv[47]	_	_
7-17	1053-1054	a	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-18	1055-1061	driver	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-19	1062-1064	of	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-20	1065-1072	obesity	abstract[42]|abstract[47]|person[48]|abstract	new[42]|giv[47]|new[48]|giv	_	_
7-21	1073-1074	,	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-22	1075-1082	insulin	abstract[42]|abstract[47]|person[48]|substance|abstract[51]	new[42]|giv[47]|new[48]|new|new[51]	coref|coref	10-24|10-24[77_51]
7-23	1083-1093	resistance	abstract[42]|abstract[47]|person[48]|abstract[51]	new[42]|giv[47]|new[48]|new[51]	_	_
7-24	1094-1095	,	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-25	1096-1099	and	abstract[42]|abstract[47]|person[48]	new[42]|giv[47]|new[48]	_	_
7-26	1100-1110	subsequent	abstract[42]|abstract[47]|person[48]|abstract[54]	new[42]|giv[47]|new[48]|new[54]	appos	7-32[0_54]
7-27	1111-1115	type	abstract[42]|abstract[47]|person[48]|abstract[52]|abstract[54]	new[42]|giv[47]|new[48]|new[52]|new[54]	_	_
7-28	1116-1117	2	abstract[42]|abstract[47]|person[48]|abstract[52]|abstract[54]	new[42]|giv[47]|new[48]|new[52]|new[54]	_	_
7-29	1118-1126	diabetes	abstract[42]|abstract[47]|person[48]|abstract|abstract[54]	new[42]|giv[47]|new[48]|new|new[54]	_	_
7-30	1127-1135	mellitus	abstract[42]|abstract[47]|person[48]|abstract[54]	new[42]|giv[47]|new[48]|new[54]	_	_
7-31	1136-1137	(	_	_	_	_
7-32	1138-1142	T2DM	abstract	giv	coref	10-29
7-33	1143-1144	)	_	_	_	_
7-34	1145-1149	have	_	_	_	_
7-35	1150-1154	been	_	_	_	_
7-36	1155-1163	revealed	_	_	_	_
7-37	1164-1165	.	_	_	_	_

#Text=For example , bypassing the proximal small intestine by means of bariatric surgery results in a significant metabolic benefit to an individual undergoing such a procedure .
8-1	1166-1169	For	_	_	_	_
8-2	1170-1177	example	_	_	_	_
8-3	1178-1179	,	_	_	_	_
8-4	1180-1189	bypassing	_	_	_	_
8-5	1190-1193	the	object[56]	new[56]	coref	12-12[95_56]
8-6	1194-1202	proximal	object[56]	new[56]	_	_
8-7	1203-1208	small	object[56]	new[56]	_	_
8-8	1209-1218	intestine	object[56]	new[56]	_	_
8-9	1219-1221	by	_	_	_	_
8-10	1222-1227	means	_	_	_	_
8-11	1228-1230	of	_	_	_	_
8-12	1231-1240	bariatric	event[57]	new[57]	_	_
8-13	1241-1248	surgery	event[57]	new[57]	_	_
8-14	1249-1256	results	_	_	_	_
8-15	1257-1259	in	_	_	_	_
8-16	1260-1261	a	abstract[58]	new[58]	_	_
8-17	1262-1273	significant	abstract[58]	new[58]	_	_
8-18	1274-1283	metabolic	abstract[58]	new[58]	_	_
8-19	1284-1291	benefit	abstract[58]	new[58]	_	_
8-20	1292-1294	to	abstract[58]	new[58]	_	_
8-21	1295-1297	an	abstract[58]|person[59]	new[58]|new[59]	_	_
8-22	1298-1308	individual	abstract[58]|person[59]	new[58]|new[59]	_	_
8-23	1309-1319	undergoing	abstract[58]|person[59]	new[58]|new[59]	_	_
8-24	1320-1324	such	abstract[58]|person[59]|event[60]	new[58]|new[59]|new[60]	_	_
8-25	1325-1326	a	abstract[58]|person[59]|event[60]	new[58]|new[59]|new[60]	_	_
8-26	1327-1336	procedure	abstract[58]|person[59]|event[60]	new[58]|new[59]|new[60]	_	_
8-27	1337-1338	.	_	_	_	_

#Text=Moreover , endoscopic procedures aimed at placing devices separating luminal contents from the duodenal mucosa result in modest weight loss and improvement in glucose homeostasis .
9-1	1339-1347	Moreover	_	_	_	_
9-2	1348-1349	,	_	_	_	_
9-3	1350-1360	endoscopic	abstract[61]	new[61]	_	_
9-4	1361-1371	procedures	abstract[61]	new[61]	_	_
9-5	1372-1377	aimed	abstract[61]	new[61]	_	_
9-6	1378-1380	at	_	_	_	_
9-7	1381-1388	placing	_	_	_	_
9-8	1389-1396	devices	object[62]	new[62]	_	_
9-9	1397-1407	separating	object[62]	new[62]	_	_
9-10	1408-1415	luminal	object[62]|substance[63]	new[62]|new[63]	_	_
9-11	1416-1424	contents	object[62]|substance[63]	new[62]|new[63]	_	_
9-12	1425-1429	from	object[62]	new[62]	_	_
9-13	1430-1433	the	object[62]|object[64]	new[62]|new[64]	coref	10-8[70_64]
9-14	1434-1442	duodenal	object[62]|object[64]	new[62]|new[64]	_	_
9-15	1443-1449	mucosa	object[62]|object[64]	new[62]|new[64]	_	_
9-16	1450-1456	result	_	_	_	_
9-17	1457-1459	in	_	_	_	_
9-18	1460-1466	modest	event[65]	new[65]	_	_
9-19	1467-1473	weight	event[65]	new[65]	_	_
9-20	1474-1478	loss	event[65]	new[65]	_	_
9-21	1479-1482	and	_	_	_	_
9-22	1483-1494	improvement	abstract[66]	new[66]	coref	10-20[74_66]
9-23	1495-1497	in	abstract[66]	new[66]	_	_
9-24	1498-1505	glucose	abstract[66]|substance|abstract[68]	new[66]|new|giv[68]	_	_
9-25	1506-1517	homeostasis	abstract[66]|abstract[68]	new[66]|giv[68]	_	_
9-26	1518-1519	.	_	_	_	_

#Text=Another endoscopic treatment which aims at resurfacing duodenal mucosa ( DMR , duodenal mucosal resurfacing ) , leads to improvement in glycemia and insulin resistance in patients with T2DM .
10-1	1520-1527	Another	event[69]	new[69]	_	_
10-2	1528-1538	endoscopic	event[69]	new[69]	_	_
10-3	1539-1548	treatment	event[69]	new[69]	_	_
10-4	1549-1554	which	event[69]	new[69]	_	_
10-5	1555-1559	aims	event[69]	new[69]	_	_
10-6	1560-1562	at	_	_	_	_
10-7	1563-1574	resurfacing	_	_	_	_
10-8	1575-1583	duodenal	object[70]	giv[70]	_	_
10-9	1584-1590	mucosa	object[70]	giv[70]	_	_
10-10	1591-1592	(	_	_	_	_
10-11	1593-1596	DMR	abstract	new	_	_
10-12	1597-1598	,	_	_	_	_
10-13	1599-1607	duodenal	event[73]	new[73]	_	_
10-14	1608-1615	mucosal	place|event[73]	new|new[73]	_	_
10-15	1616-1627	resurfacing	event[73]	new[73]	_	_
10-16	1628-1629	)	_	_	_	_
10-17	1630-1631	,	_	_	_	_
10-18	1632-1637	leads	_	_	_	_
10-19	1638-1640	to	_	_	_	_
10-20	1641-1652	improvement	abstract[74]	giv[74]	_	_
10-21	1653-1655	in	abstract[74]	giv[74]	_	_
10-22	1656-1664	glycemia	abstract[74]|abstract	giv[74]|new	_	_
10-23	1665-1668	and	abstract[74]	giv[74]	_	_
10-24	1669-1676	insulin	abstract[74]|substance|abstract[77]	giv[74]|giv|giv[77]	_	_
10-25	1677-1687	resistance	abstract[74]|abstract[77]	giv[74]|giv[77]	_	_
10-26	1688-1690	in	abstract[74]	giv[74]	_	_
10-27	1691-1699	patients	abstract[74]|person[78]	giv[74]|new[78]	coref	25-6[216_78]
10-28	1700-1704	with	abstract[74]|person[78]	giv[74]|new[78]	_	_
10-29	1705-1709	T2DM	abstract[74]|person[78]|abstract	giv[74]|new[78]|giv	ana	11-1
10-30	1710-1711	.	_	_	_	_

#Text=It is not surprising when we recall that SB endocrine cells secrete glycemia-regulating incretin hormones ( e.g. , glucagon-like peptide , GLP-1 ) , and this process is dependent on food content in the intestinal lumen .
11-1	1712-1714	It	abstract	giv	_	_
11-2	1715-1717	is	_	_	_	_
11-3	1718-1721	not	_	_	_	_
11-4	1722-1732	surprising	_	_	_	_
11-5	1733-1737	when	_	_	_	_
11-6	1738-1740	we	person	acc	_	_
11-7	1741-1747	recall	_	_	_	_
11-8	1748-1752	that	_	_	_	_
11-9	1753-1755	SB	abstract|place[83]	giv|giv[83]	coref|coref	16-18[134_83]|24-30[214_0]
11-10	1756-1765	endocrine	place[83]	giv[83]	_	_
11-11	1766-1771	cells	place[83]	giv[83]	_	_
11-12	1772-1779	secrete	_	_	_	_
11-13	1780-1799	glycemia-regulating	substance[84]	new[84]	appos	11-17[85_84]
11-14	1800-1808	incretin	substance[84]	new[84]	_	_
11-15	1809-1817	hormones	substance[84]	new[84]	_	_
11-16	1818-1819	(	_	_	_	_
11-17	1820-1824	e.g.	substance[85]	giv[85]	coref	15-27[124_85]
11-18	1825-1826	,	substance[85]	giv[85]	_	_
11-19	1827-1840	glucagon-like	substance[85]	giv[85]	_	_
11-20	1841-1848	peptide	substance[85]	giv[85]	_	_
11-21	1849-1850	,	_	_	_	_
11-22	1851-1856	GLP-1	abstract	new	_	_
11-23	1857-1858	)	_	_	_	_
11-24	1859-1860	,	_	_	_	_
11-25	1861-1864	and	_	_	_	_
11-26	1865-1869	this	event[87]	new[87]	coref	21-11[175_87]
11-27	1870-1877	process	event[87]	new[87]	_	_
11-28	1878-1880	is	_	_	_	_
11-29	1881-1890	dependent	_	_	_	_
11-30	1891-1893	on	_	_	_	_
11-31	1894-1898	food	substance|abstract[89]	new|new[89]	_	_
11-32	1899-1906	content	abstract[89]	new[89]	_	_
11-33	1907-1909	in	abstract[89]	new[89]	_	_
11-34	1910-1913	the	abstract[89]|substance[90]	new[89]|new[90]	_	_
11-35	1914-1924	intestinal	abstract[89]|substance[90]	new[89]|new[90]	_	_
11-36	1925-1930	lumen	abstract[89]|substance[90]	new[89]|new[90]	_	_
11-37	1931-1932	.	_	_	_	_

#Text=Moreover , bile acids with various targets in the liver and small intestine ( e.g. , farnesoid receptor , FXR ) together with a plethora of other small signaling molecules act in concert in regulating metabolic and digestive GI function .
12-1	1933-1941	Moreover	_	_	_	_
12-2	1942-1943	,	_	_	_	_
12-3	1944-1948	bile	object|substance[92]	new|new[92]	appos	12-15[97_92]
12-4	1949-1954	acids	substance[92]	new[92]	_	_
12-5	1955-1959	with	substance[92]	new[92]	_	_
12-6	1960-1967	various	substance[92]|abstract[93]	new[92]|new[93]	_	_
12-7	1968-1975	targets	substance[92]|abstract[93]	new[92]|new[93]	_	_
12-8	1976-1978	in	substance[92]|abstract[93]	new[92]|new[93]	_	_
12-9	1979-1982	the	substance[92]|abstract[93]|object[94]	new[92]|new[93]|new[94]	coref	25-27[0_94]
12-10	1983-1988	liver	substance[92]|abstract[93]|object[94]	new[92]|new[93]|new[94]	_	_
12-11	1989-1992	and	substance[92]|abstract[93]	new[92]|new[93]	_	_
12-12	1993-1998	small	substance[92]|abstract[93]|object[95]	new[92]|new[93]|giv[95]	coref	23-17[197_95]
12-13	1999-2008	intestine	substance[92]|abstract[93]|object[95]	new[92]|new[93]|giv[95]	_	_
12-14	2009-2010	(	_	_	_	_
12-15	2011-2015	e.g.	substance[97]	giv[97]	coref	15-37[127_97]
12-16	2016-2017	,	substance[97]	giv[97]	_	_
12-17	2018-2027	farnesoid	object|substance[97]	new|giv[97]	_	_
12-18	2028-2036	receptor	substance[97]	giv[97]	_	_
12-19	2037-2038	,	_	_	_	_
12-20	2039-2042	FXR	abstract	new	_	_
12-21	2043-2044	)	_	_	_	_
12-22	2045-2053	together	abstract[99]	new[99]	_	_
12-23	2054-2058	with	abstract[99]	new[99]	_	_
12-24	2059-2060	a	abstract[99]	new[99]	_	_
12-25	2061-2069	plethora	abstract[99]	new[99]	_	_
12-26	2070-2072	of	abstract[99]	new[99]	_	_
12-27	2073-2078	other	abstract[99]|object[100]	new[99]|new[100]	_	_
12-28	2079-2084	small	abstract[99]|object[100]	new[99]|new[100]	_	_
12-29	2085-2094	signaling	abstract[99]|object[100]	new[99]|new[100]	_	_
12-30	2095-2104	molecules	abstract[99]|object[100]	new[99]|new[100]	_	_
12-31	2105-2108	act	_	_	_	_
12-32	2109-2111	in	_	_	_	_
12-33	2112-2119	concert	_	_	_	_
12-34	2120-2122	in	_	_	_	_
12-35	2123-2133	regulating	_	_	_	_
12-36	2134-2143	metabolic	abstract[102]	new[102]	coref	17-7[143_102]
12-37	2144-2147	and	abstract[102]	new[102]	_	_
12-38	2148-2157	digestive	abstract[102]	new[102]	_	_
12-39	2158-2160	GI	organization|abstract[102]	new|new[102]	_	_
12-40	2161-2169	function	abstract[102]	new[102]	_	_
12-41	2170-2171	.	_	_	_	_

#Text=The human digestive tract and enteric nervous system ( ENS ) communicate with the central nervous system ( CNS ) through the gut-brain axis ( GBA ) .
13-1	2172-2175	The	object[103]|object[104]	giv[103]|giv[104]	_	_
13-2	2176-2181	human	object[103]|object[104]	giv[103]|giv[104]	_	_
13-3	2182-2191	digestive	object[103]|object[104]	giv[103]|giv[104]	_	_
13-4	2192-2197	tract	object[103]|object[104]	giv[103]|giv[104]	_	_
13-5	2198-2201	and	object[104]	giv[104]	_	_
13-6	2202-2209	enteric	object[104]|abstract[105]	giv[104]|giv[105]	appos	13-10[0_105]
13-7	2210-2217	nervous	object[104]|abstract[105]	giv[104]|giv[105]	_	_
13-8	2218-2224	system	object[104]|abstract[105]	giv[104]|giv[105]	_	_
13-9	2225-2226	(	_	_	_	_
13-10	2227-2230	ENS	abstract	giv	coref	13-14[107_0]
13-11	2231-2232	)	_	_	_	_
13-12	2233-2244	communicate	_	_	_	_
13-13	2245-2249	with	_	_	_	_
13-14	2250-2253	the	abstract[107]	giv[107]	appos	13-19[0_107]
13-15	2254-2261	central	abstract[107]	giv[107]	_	_
13-16	2262-2269	nervous	abstract[107]	giv[107]	_	_
13-17	2270-2276	system	abstract[107]	giv[107]	_	_
13-18	2277-2278	(	_	_	_	_
13-19	2279-2282	CNS	abstract	giv	coref	14-18[117_0]
13-20	2283-2284	)	_	_	_	_
13-21	2285-2292	through	_	_	_	_
13-22	2293-2296	the	abstract[110]	new[110]	appos	13-26[0_110]
13-23	2297-2306	gut-brain	object|abstract[110]	new|new[110]	coref	31-6
13-24	2307-2311	axis	abstract[110]	new[110]	_	_
13-25	2312-2313	(	_	_	_	_
13-26	2314-2317	GBA	abstract	giv	coref	15-7[120_0]
13-27	2318-2319	)	_	_	_	_
13-28	2320-2321	.	_	_	_	_

#Text=This bidirectional communication involves diverse neural networks through the X cranial vagal nerve — dorsal roots of the sympathetic/ parasympathetic nervous system .
14-1	2322-2326	This	abstract[112]	new[112]	coref	18-1[149_112]
14-2	2327-2340	bidirectional	abstract[112]	new[112]	_	_
14-3	2341-2354	communication	abstract[112]	new[112]	_	_
14-4	2355-2363	involves	_	_	_	_
14-5	2364-2371	diverse	abstract[113]	new[113]	_	_
14-6	2372-2378	neural	abstract[113]	new[113]	_	_
14-7	2379-2387	networks	abstract[113]	new[113]	_	_
14-8	2388-2395	through	_	_	_	_
14-9	2396-2399	the	object[115]	new[115]	appos	14-15[116_115]
14-10	2400-2401	X	object[115]	new[115]	_	_
14-11	2402-2409	cranial	object[115]	new[115]	_	_
14-12	2410-2415	vagal	object|object[115]	new|new[115]	_	_
14-13	2416-2421	nerve	object[115]	new[115]	_	_
14-14	2422-2423	—	_	_	_	_
14-15	2424-2430	dorsal	object[116]	giv[116]	_	_
14-16	2431-2436	roots	object[116]	giv[116]	_	_
14-17	2437-2439	of	object[116]	giv[116]	_	_
14-18	2440-2443	the	object[116]|abstract[117]	giv[116]|giv[117]	coref	21-28[183_117]
14-19	2444-2456	sympathetic/	object[116]|abstract[117]	giv[116]|giv[117]	_	_
14-20	2457-2472	parasympathetic	object[116]|abstract[117]	giv[116]|giv[117]	_	_
14-21	2473-2480	nervous	object[116]|abstract[117]	giv[116]|giv[117]	_	_
14-22	2481-2487	system	object[116]|abstract[117]	giv[116]|giv[117]	_	_
14-23	2488-2489	.	_	_	_	_

#Text=Important roles in the regulation of the gut-brain axis are played by : ( i ) the hypothalamus-pituitary-adrenal axis ( HPA ) , ( ii ) the stress hormones ( cortisol ) , ( iii ) the short-chain fatty acids ( SCFAs ) , and ( iv ) the gut microbiota .
15-1	2490-2499	Important	abstract[118]	new[118]	_	_
15-2	2500-2505	roles	abstract[118]	new[118]	_	_
15-3	2506-2508	in	abstract[118]	new[118]	_	_
15-4	2509-2512	the	abstract[118]|abstract[119]	new[118]|new[119]	_	_
15-5	2513-2523	regulation	abstract[118]|abstract[119]	new[118]|new[119]	_	_
15-6	2524-2526	of	abstract[118]|abstract[119]	new[118]|new[119]	_	_
15-7	2527-2530	the	abstract[118]|abstract[119]|abstract[120]	new[118]|new[119]|giv[120]	coref	15-17[121_120]
15-8	2531-2540	gut-brain	abstract[118]|abstract[119]|abstract[120]	new[118]|new[119]|giv[120]	_	_
15-9	2541-2545	axis	abstract[118]|abstract[119]|abstract[120]	new[118]|new[119]|giv[120]	_	_
15-10	2546-2549	are	_	_	_	_
15-11	2550-2556	played	_	_	_	_
15-12	2557-2559	by	_	_	_	_
15-13	2560-2561	:	_	_	_	_
15-14	2562-2563	(	_	_	_	_
15-15	2564-2565	i	_	_	_	_
15-16	2566-2567	)	_	_	_	_
15-17	2568-2571	the	abstract[121]	giv[121]	appos	15-21[0_121]
15-18	2572-2602	hypothalamus-pituitary-adrenal	abstract[121]	giv[121]	_	_
15-19	2603-2607	axis	abstract[121]	giv[121]	_	_
15-20	2608-2609	(	_	_	_	_
15-21	2610-2613	HPA	abstract	giv	coref	16-9
15-22	2614-2615	)	_	_	_	_
15-23	2616-2617	,	_	_	_	_
15-24	2618-2619	(	_	_	_	_
15-25	2620-2622	ii	_	_	_	_
15-26	2623-2624	)	_	_	_	_
15-27	2625-2628	the	substance[124]	giv[124]	appos	15-31[0_124]
15-28	2629-2635	stress	abstract|substance[124]	new|giv[124]	_	_
15-29	2636-2644	hormones	substance[124]	giv[124]	_	_
15-30	2645-2646	(	_	_	_	_
15-31	2647-2655	cortisol	substance	giv	_	_
15-32	2656-2657	)	_	_	_	_
15-33	2658-2659	,	_	_	_	_
15-34	2660-2661	(	_	_	_	_
15-35	2662-2665	iii	_	_	_	_
15-36	2666-2667	)	_	_	_	_
15-37	2668-2671	the	substance[127]	giv[127]	_	_
15-38	2672-2683	short-chain	substance[127]	giv[127]	_	_
15-39	2684-2689	fatty	abstract|substance[127]	new|giv[127]	_	_
15-40	2690-2695	acids	substance[127]	giv[127]	_	_
15-41	2696-2697	(	_	_	_	_
15-42	2698-2703	SCFAs	abstract	new	_	_
15-43	2704-2705	)	_	_	_	_
15-44	2706-2707	,	_	_	_	_
15-45	2708-2711	and	_	_	_	_
15-46	2712-2713	(	_	_	_	_
15-47	2714-2716	iv	_	_	_	_
15-48	2717-2718	)	_	_	_	_
15-49	2719-2722	the	substance[130]	new[130]	coref	16-26[0_130]
15-50	2723-2726	gut	abstract|substance[130]	new|new[130]	coref	24-21
15-51	2727-2737	microbiota	substance[130]	new[130]	_	_
15-52	2738-2739	.	_	_	_	_

#Text=The intestinal barrier , another important part of GBA , is composed of : ( i ) goblet cells derived mucus , ( ii ) microbiota , ( iii ) epithelial cells , ( iv ) endothelial cells , ( v ) lymphatic vessels , and v ) enterocytes ’ tight cellular junctions .
16-1	2740-2743	The	object[131]	new[131]	coref	17-9[144_131]
16-2	2744-2754	intestinal	object[131]	new[131]	_	_
16-3	2755-2762	barrier	object[131]	new[131]	_	_
16-4	2763-2764	,	_	_	_	_
16-5	2765-2772	another	_	_	_	_
16-6	2773-2782	important	_	_	_	_
16-7	2783-2787	part	_	_	_	_
16-8	2788-2790	of	_	_	_	_
16-9	2791-2794	GBA	abstract	giv	_	_
16-10	2795-2796	,	_	_	_	_
16-11	2797-2799	is	_	_	_	_
16-12	2800-2808	composed	_	_	_	_
16-13	2809-2811	of	_	_	_	_
16-14	2812-2813	:	_	_	_	_
16-15	2814-2815	(	_	_	_	_
16-16	2816-2817	i	_	_	_	_
16-17	2818-2819	)	_	_	_	_
16-18	2820-2826	goblet	object|place[134]|substance[135]	new|giv[134]|new[135]	coref	16-31[137_134]
16-19	2827-2832	cells	place[134]|substance[135]	giv[134]|new[135]	_	_
16-20	2833-2840	derived	substance[135]	new[135]	_	_
16-21	2841-2846	mucus	substance[135]	new[135]	_	_
16-22	2847-2848	,	_	_	_	_
16-23	2849-2850	(	_	_	_	_
16-24	2851-2853	ii	_	_	_	_
16-25	2854-2855	)	_	_	_	_
16-26	2856-2866	microbiota	substance	giv	_	_
16-27	2867-2868	,	_	_	_	_
16-28	2869-2870	(	_	_	_	_
16-29	2871-2874	iii	_	_	_	_
16-30	2875-2876	)	_	_	_	_
16-31	2877-2887	epithelial	place[137]	giv[137]	coref	16-37[138_137]
16-32	2888-2893	cells	place[137]	giv[137]	_	_
16-33	2894-2895	,	_	_	_	_
16-34	2896-2897	(	_	_	_	_
16-35	2898-2900	iv	_	_	_	_
16-36	2901-2902	)	_	_	_	_
16-37	2903-2914	endothelial	place[138]	giv[138]	_	_
16-38	2915-2920	cells	place[138]	giv[138]	_	_
16-39	2921-2922	,	_	_	_	_
16-40	2923-2924	(	_	_	_	_
16-41	2925-2926	v	_	_	_	_
16-42	2927-2928	)	_	_	_	_
16-43	2929-2938	lymphatic	object[139]	new[139]	_	_
16-44	2939-2946	vessels	object[139]	new[139]	_	_
16-45	2947-2948	,	_	_	_	_
16-46	2949-2952	and	_	_	_	_
16-47	2953-2954	v	abstract[140]|place[141]	new[140]|new[141]	_	_
16-48	2955-2956	)	abstract[140]|place[141]	new[140]|new[141]	_	_
16-49	2957-2968	enterocytes	abstract[140]|place[141]	new[140]|new[141]	_	_
16-50	2969-2970	’	abstract[140]|place[141]	new[140]|new[141]	_	_
16-51	2971-2976	tight	place[141]	new[141]	_	_
16-52	2977-2985	cellular	place[141]	new[141]	_	_
16-53	2986-2995	junctions	place[141]	new[141]	_	_
16-54	2996-2997	.	_	_	_	_

#Text=Of interest , the structure and function of the intestinal barrier resemble that of the blood-brain barrier ( BBB ) .
17-1	2998-3000	Of	_	_	_	_
17-2	3001-3009	interest	_	_	_	_
17-3	3010-3011	,	_	_	_	_
17-4	3012-3015	the	abstract[142]	new[142]	_	_
17-5	3016-3025	structure	abstract[142]	new[142]	_	_
17-6	3026-3029	and	_	_	_	_
17-7	3030-3038	function	abstract[143]	giv[143]	coref	20-21[169_143]
17-8	3039-3041	of	abstract[143]	giv[143]	_	_
17-9	3042-3045	the	abstract[143]|object[144]	giv[143]|giv[144]	ana	17-13[145_144]
17-10	3046-3056	intestinal	abstract[143]|object[144]	giv[143]|giv[144]	_	_
17-11	3057-3064	barrier	abstract[143]|object[144]	giv[143]|giv[144]	_	_
17-12	3065-3073	resemble	_	_	_	_
17-13	3074-3078	that	object[145]	giv[145]	coref	17-15[147_145]
17-14	3079-3081	of	object[145]	giv[145]	_	_
17-15	3082-3085	the	object[145]|object[147]	giv[145]|giv[147]	coref	19-11[156_147]
17-16	3086-3097	blood-brain	object[145]|substance|object[147]	giv[145]|new|giv[147]	_	_
17-17	3098-3105	barrier	object[145]|object[147]	giv[145]|giv[147]	_	_
17-18	3106-3107	(	_	_	_	_
17-19	3108-3111	BBB	abstract	new	_	_
17-20	3112-3113	)	_	_	_	_
17-21	3114-3115	.	_	_	_	_

#Text=The gut-brain communication is mediated via blood , portal/hepatic circulation , and the bone marrow .
18-1	3116-3119	The	abstract[149]	giv[149]	_	_
18-2	3120-3129	gut-brain	abstract[149]	giv[149]	_	_
18-3	3130-3143	communication	abstract[149]	giv[149]	_	_
18-4	3144-3146	is	_	_	_	_
18-5	3147-3155	mediated	_	_	_	_
18-6	3156-3159	via	_	_	_	_
18-7	3160-3165	blood	substance	new	_	_
18-8	3166-3167	,	_	_	_	_
18-9	3168-3182	portal/hepatic	abstract[151]	new[151]	ana	19-3[0_151]
18-10	3183-3194	circulation	abstract[151]	new[151]	_	_
18-11	3195-3196	,	_	_	_	_
18-12	3197-3200	and	_	_	_	_
18-13	3201-3204	the	object[153]	new[153]	_	_
18-14	3205-3209	bone	object|object[153]	new|new[153]	_	_
18-15	3210-3216	marrow	object[153]	new[153]	_	_
18-16	3217-3218	.	_	_	_	_

#Text=Recently , it has been described that the alterations of the intestinal barrier play a crucial role in the pathology of several human inflammatory and autoimmune diseases .
19-1	3219-3227	Recently	_	_	_	_
19-2	3228-3229	,	_	_	_	_
19-3	3230-3232	it	abstract	giv	_	_
19-4	3233-3236	has	_	_	_	_
19-5	3237-3241	been	_	_	_	_
19-6	3242-3251	described	_	_	_	_
19-7	3252-3256	that	_	_	_	_
19-8	3257-3260	the	abstract[155]	new[155]	coref	21-14[177_155]
19-9	3261-3272	alterations	abstract[155]	new[155]	_	_
19-10	3273-3275	of	abstract[155]	new[155]	_	_
19-11	3276-3279	the	abstract[155]|object[156]	new[155]|giv[156]	coref	20-21[168_156]
19-12	3280-3290	intestinal	abstract[155]|object[156]	new[155]|giv[156]	_	_
19-13	3291-3298	barrier	abstract[155]|object[156]	new[155]|giv[156]	_	_
19-14	3299-3303	play	_	_	_	_
19-15	3304-3305	a	abstract[157]	giv[157]	_	_
19-16	3306-3313	crucial	abstract[157]	giv[157]	_	_
19-17	3314-3318	role	abstract[157]	giv[157]	_	_
19-18	3319-3321	in	abstract[157]	giv[157]	_	_
19-19	3322-3325	the	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
19-20	3326-3335	pathology	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
19-21	3336-3338	of	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
19-22	3339-3346	several	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	coref	34-24[293_159]
19-23	3347-3352	human	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	_	_
19-24	3353-3365	inflammatory	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	_	_
19-25	3366-3369	and	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	_	_
19-26	3370-3380	autoimmune	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	_	_
19-27	3381-3389	diseases	abstract[157]|abstract[158]|abstract[159]	giv[157]|new[158]|giv[159]	_	_
19-28	3390-3391	.	_	_	_	_

#Text=Mohanan et al. documented the crucial role of the C1orf106 inflammatory bowel disease ( IBD ) susceptibility gene in stabilizing intestinal barrier function and intestinal inflammation .
20-1	3392-3399	Mohanan	person	new	_	_
20-2	3400-3402	et	_	_	_	_
20-3	3403-3406	al.	_	_	_	_
20-4	3407-3417	documented	_	_	_	_
20-5	3418-3421	the	abstract[161]	new[161]	_	_
20-6	3422-3429	crucial	abstract[161]	new[161]	_	_
20-7	3430-3434	role	abstract[161]	new[161]	_	_
20-8	3435-3437	of	abstract[161]	new[161]	_	_
20-9	3438-3441	the	abstract[161]|abstract[167]	new[161]|new[167]	coref	24-7[204_167]
20-10	3442-3450	C1orf106	abstract[161]|abstract|abstract[164]|abstract[167]	new[161]|new|new[164]|new[167]	appos	20-15[0_164]
20-11	3451-3463	inflammatory	abstract[161]|abstract[164]|abstract[167]	new[161]|new[164]|new[167]	_	_
20-12	3464-3469	bowel	abstract[161]|object|abstract[164]|abstract[167]	new[161]|giv|new[164]|new[167]	coref	30-11[269_0]
20-13	3470-3477	disease	abstract[161]|abstract[164]|abstract[167]	new[161]|new[164]|new[167]	_	_
20-14	3478-3479	(	abstract[161]|abstract[167]	new[161]|new[167]	_	_
20-15	3480-3483	IBD	abstract[161]|abstract|abstract[167]	new[161]|giv|new[167]	coref	25-8[218_0]
20-16	3484-3485	)	abstract[161]|abstract[167]	new[161]|new[167]	_	_
20-17	3486-3500	susceptibility	abstract[161]|abstract|abstract[167]	new[161]|new|new[167]	_	_
20-18	3501-3505	gene	abstract[161]|abstract[167]	new[161]|new[167]	_	_
20-19	3506-3508	in	_	_	_	_
20-20	3509-3520	stabilizing	_	_	_	_
20-21	3521-3531	intestinal	object[168]|abstract[169]	giv[168]|giv[169]	coref	21-15[0_168]
20-22	3532-3539	barrier	object[168]|abstract[169]	giv[168]|giv[169]	_	_
20-23	3540-3548	function	abstract[169]	giv[169]	_	_
20-24	3549-3552	and	_	_	_	_
20-25	3553-3563	intestinal	abstract[170]	new[170]	coref	22-16[191_170]
20-26	3564-3576	inflammation	abstract[170]	new[170]	_	_
20-27	3577-3578	.	_	_	_	_

#Text=Manfredo Vieira et al. evidenced the role of pathobionts in the process of intestinal barrier alterations , which were followed by their translocation to lymph nodes and the hepatic portal system , triggering systemic lupus erythematosus ( SLE ) .
21-1	3579-3587	Manfredo	person[171]	new[171]	_	_
21-2	3588-3594	Vieira	person[171]	new[171]	_	_
21-3	3595-3597	et	_	_	_	_
21-4	3598-3601	al.	person	new	ana	21-22
21-5	3602-3611	evidenced	_	_	_	_
21-6	3612-3615	the	abstract[173]	new[173]	_	_
21-7	3616-3620	role	abstract[173]	new[173]	_	_
21-8	3621-3623	of	abstract[173]	new[173]	_	_
21-9	3624-3635	pathobionts	abstract[173]|substance[174]	new[173]|new[174]	_	_
21-10	3636-3638	in	abstract[173]|substance[174]	new[173]|new[174]	_	_
21-11	3639-3642	the	abstract[173]|substance[174]|event[175]	new[173]|new[174]|giv[175]	_	_
21-12	3643-3650	process	abstract[173]|substance[174]|event[175]	new[173]|new[174]|giv[175]	_	_
21-13	3651-3653	of	abstract[173]|substance[174]|event[175]	new[173]|new[174]|giv[175]	_	_
21-14	3654-3664	intestinal	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-15	3665-3672	barrier	abstract[173]|substance[174]|event[175]|object|abstract[177]	new[173]|new[174]|giv[175]|giv|giv[177]	coref	22-11[190_0]
21-16	3673-3684	alterations	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-17	3685-3686	,	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-18	3687-3692	which	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-19	3693-3697	were	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-20	3698-3706	followed	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-21	3707-3709	by	abstract[173]|substance[174]|event[175]|abstract[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
21-22	3710-3715	their	abstract[173]|substance[174]|event[175]|abstract[177]|person|abstract[179]	new[173]|new[174]|giv[175]|giv[177]|giv|new[179]	_	_
21-23	3716-3729	translocation	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]	new[173]|new[174]|giv[175]|giv[177]|new[179]	_	_
21-24	3730-3732	to	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]	new[173]|new[174]|giv[175]|giv[177]|new[179]	_	_
21-25	3733-3738	lymph	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|person|object[181]	new[173]|new[174]|giv[175]|giv[177]|new[179]|new|new[181]	_	_
21-26	3739-3744	nodes	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|object[181]	new[173]|new[174]|giv[175]|giv[177]|new[179]|new[181]	_	_
21-27	3745-3748	and	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]	new[173]|new[174]|giv[175]|giv[177]|new[179]	_	_
21-28	3749-3752	the	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|abstract[183]	new[173]|new[174]|giv[175]|giv[177]|new[179]|giv[183]	_	_
21-29	3753-3760	hepatic	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|abstract[183]	new[173]|new[174]|giv[175]|giv[177]|new[179]|giv[183]	_	_
21-30	3761-3767	portal	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|object|abstract[183]	new[173]|new[174]|giv[175]|giv[177]|new[179]|new|giv[183]	_	_
21-31	3768-3774	system	abstract[173]|substance[174]|event[175]|abstract[177]|abstract[179]|abstract[183]	new[173]|new[174]|giv[175]|giv[177]|new[179]|giv[183]	_	_
21-32	3775-3776	,	_	_	_	_
21-33	3777-3787	triggering	_	_	_	_
21-34	3788-3796	systemic	abstract[185]	new[185]	appos	21-38[0_185]
21-35	3797-3802	lupus	substance|abstract[185]	new|new[185]	_	_
21-36	3803-3816	erythematosus	abstract[185]	new[185]	_	_
21-37	3817-3818	(	_	_	_	_
21-38	3819-3822	SLE	abstract	giv	_	_
21-39	3823-3824	)	_	_	_	_
21-40	3825-3826	.	_	_	_	_

#Text=Thaiss et al. reported that hyperglycemia leads to disruption of the intestinal barrier followed by intestinal inflammation and systemic infection .
22-1	3827-3833	Thaiss	person	new	_	_
22-2	3834-3836	et	_	_	_	_
22-3	3837-3840	al.	_	_	_	_
22-4	3841-3849	reported	_	_	_	_
22-5	3850-3854	that	_	_	_	_
22-6	3855-3868	hyperglycemia	abstract	new	_	_
22-7	3869-3874	leads	_	_	_	_
22-8	3875-3877	to	_	_	_	_
22-9	3878-3888	disruption	event[189]	new[189]	_	_
22-10	3889-3891	of	event[189]	new[189]	_	_
22-11	3892-3895	the	event[189]|object[190]	new[189]|giv[190]	coref	23-10[195_190]
22-12	3896-3906	intestinal	event[189]|object[190]	new[189]|giv[190]	_	_
22-13	3907-3914	barrier	event[189]|object[190]	new[189]|giv[190]	_	_
22-14	3915-3923	followed	_	_	_	_
22-15	3924-3926	by	_	_	_	_
22-16	3927-3937	intestinal	abstract[191]	giv[191]	_	_
22-17	3938-3950	inflammation	abstract[191]	giv[191]	_	_
22-18	3951-3954	and	_	_	_	_
22-19	3955-3963	systemic	event[192]	new[192]	_	_
22-20	3964-3973	infection	event[192]	new[192]	_	_
22-21	3974-3975	.	_	_	_	_

#Text=Spadoni et al. recently documented that the presence of the gut-vascular barrier ( GVB ) in the small intestine controls the dissemination of bacteria into the bloodstream .
23-1	3976-3983	Spadoni	person	new	_	_
23-2	3984-3986	et	_	_	_	_
23-3	3987-3990	al.	_	_	_	_
23-4	3991-3999	recently	_	_	_	_
23-5	4000-4010	documented	_	_	_	_
23-6	4011-4015	that	_	_	_	_
23-7	4016-4019	the	abstract[194]	new[194]	_	_
23-8	4020-4028	presence	abstract[194]	new[194]	_	_
23-9	4029-4031	of	abstract[194]	new[194]	_	_
23-10	4032-4035	the	abstract[194]|object[195]	new[194]|giv[195]	_	_
23-11	4036-4048	gut-vascular	abstract[194]|object[195]	new[194]|giv[195]	_	_
23-12	4049-4056	barrier	abstract[194]|object[195]	new[194]|giv[195]	_	_
23-13	4057-4058	(	_	_	_	_
23-14	4059-4062	GVB	abstract	new	coref	25-1[215_0]
23-15	4063-4064	)	_	_	_	_
23-16	4065-4067	in	_	_	_	_
23-17	4068-4071	the	object[197]	giv[197]	coref	26-13[231_197]
23-18	4072-4077	small	object[197]	giv[197]	_	_
23-19	4078-4087	intestine	object[197]	giv[197]	_	_
23-20	4088-4096	controls	_	_	_	_
23-21	4097-4100	the	abstract[198]	new[198]	_	_
23-22	4101-4114	dissemination	abstract[198]	new[198]	_	_
23-23	4115-4117	of	abstract[198]	new[198]	_	_
23-24	4118-4126	bacteria	abstract[198]|animal	new[198]|new	_	_
23-25	4127-4131	into	abstract[198]	new[198]	_	_
23-26	4132-4135	the	abstract[198]|substance[200]	new[198]|new[200]	_	_
23-27	4136-4147	bloodstream	abstract[198]|substance[200]	new[198]|new[200]	_	_
23-28	4148-4149	.	_	_	_	_

#Text=The authors reported a decrease of the wnt/beta catenin-inducible gene Axin2 ( a marker of stem cell renewal ) in gut endothelium under the presence of Salmonella typhimirum in the SB .
24-1	4150-4153	The	person[201]	new[201]	_	_
24-2	4154-4161	authors	person[201]	new[201]	_	_
24-3	4162-4170	reported	_	_	_	_
24-4	4171-4172	a	event[202]	new[202]	_	_
24-5	4173-4181	decrease	event[202]	new[202]	_	_
24-6	4182-4184	of	event[202]	new[202]	_	_
24-7	4185-4188	the	event[202]|abstract[204]|abstract[205]	new[202]|giv[204]|new[205]	appos	24-13[206_204]
24-8	4189-4197	wnt/beta	event[202]|abstract|abstract[204]|abstract[205]	new[202]|new|giv[204]|new[205]	_	_
24-9	4198-4215	catenin-inducible	event[202]|abstract[204]|abstract[205]	new[202]|giv[204]|new[205]	_	_
24-10	4216-4220	gene	event[202]|abstract[204]|abstract[205]	new[202]|giv[204]|new[205]	_	_
24-11	4221-4226	Axin2	event[202]|abstract[205]	new[202]|new[205]	_	_
24-12	4227-4228	(	event[202]	new[202]	_	_
24-13	4229-4230	a	event[202]|abstract[206]	new[202]|giv[206]	coref	26-26[237_206]
24-14	4231-4237	marker	event[202]|abstract[206]	new[202]|giv[206]	_	_
24-15	4238-4240	of	event[202]|abstract[206]	new[202]|giv[206]	_	_
24-16	4241-4245	stem	event[202]|abstract[206]|place[207]|event[208]	new[202]|giv[206]|new[207]|new[208]	_	_
24-17	4246-4250	cell	event[202]|abstract[206]|place[207]|event[208]	new[202]|giv[206]|new[207]|new[208]	_	_
24-18	4251-4258	renewal	event[202]|abstract[206]|event[208]	new[202]|giv[206]|new[208]	_	_
24-19	4259-4260	)	event[202]	new[202]	_	_
24-20	4261-4263	in	event[202]	new[202]	_	_
24-21	4264-4267	gut	event[202]|abstract|object[210]	new[202]|giv|new[210]	_	_
24-22	4268-4279	endothelium	event[202]|object[210]	new[202]|new[210]	_	_
24-23	4280-4285	under	event[202]	new[202]	_	_
24-24	4286-4289	the	event[202]|abstract[211]	new[202]|new[211]	_	_
24-25	4290-4298	presence	event[202]|abstract[211]	new[202]|new[211]	_	_
24-26	4299-4301	of	event[202]|abstract[211]	new[202]|new[211]	_	_
24-27	4302-4312	Salmonella	event[202]|abstract[211]|animal	new[202]|new[211]|new	_	_
24-28	4313-4323	typhimirum	event[202]|abstract[211]|abstract[213]	new[202]|new[211]|new[213]	_	_
24-29	4324-4326	in	event[202]|abstract[211]|abstract[213]	new[202]|new[211]|new[213]	_	_
24-30	4327-4330	the	event[202]|abstract[211]|abstract[213]|abstract[214]	new[202]|new[211]|new[213]|giv[214]	coref	27-4[0_214]
24-31	4331-4333	SB	event[202]|abstract[211]|abstract[213]|abstract[214]	new[202]|new[211]|new[213]|giv[214]	_	_
24-32	4334-4335	.	_	_	_	_

#Text=The GVB was modified in patients with coeliac disease ( CD ) with altered serum transaminases , which suggests that GVB deterioration may be responsible for liver damage in CD patients .
25-1	4336-4339	The	abstract[215]	giv[215]	coref	25-21[0_215]
25-2	4340-4343	GVB	abstract[215]	giv[215]	_	_
25-3	4344-4347	was	_	_	_	_
25-4	4348-4356	modified	_	_	_	_
25-5	4357-4359	in	_	_	_	_
25-6	4360-4368	patients	person[216]	giv[216]	coref	25-30[227_216]
25-7	4369-4373	with	person[216]	giv[216]	_	_
25-8	4374-4381	coeliac	person[216]|person|abstract[218]	giv[216]|new|giv[218]	appos	25-11[0_218]
25-9	4382-4389	disease	person[216]|abstract[218]	giv[216]|giv[218]	_	_
25-10	4390-4391	(	person[216]	giv[216]	_	_
25-11	4392-4394	CD	person[216]|abstract	giv[216]|giv	coref	25-30
25-12	4395-4396	)	person[216]	giv[216]	_	_
25-13	4397-4401	with	person[216]	giv[216]	_	_
25-14	4402-4409	altered	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-15	4410-4415	serum	person[216]|substance|abstract[221]	giv[216]|new|new[221]	_	_
25-16	4416-4429	transaminases	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-17	4430-4431	,	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-18	4432-4437	which	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-19	4438-4446	suggests	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-20	4447-4451	that	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-21	4452-4455	GVB	person[216]|abstract[221]|abstract|abstract[223]	giv[216]|new[221]|giv|new[223]	ana|coref	26-1[0_223]|26-26
25-22	4456-4469	deterioration	person[216]|abstract[221]|abstract[223]	giv[216]|new[221]|new[223]	_	_
25-23	4470-4473	may	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-24	4474-4476	be	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-25	4477-4488	responsible	person[216]|abstract[221]	giv[216]|new[221]	_	_
25-26	4489-4492	for	_	_	_	_
25-27	4493-4498	liver	object|event[225]	giv|new[225]	_	_
25-28	4499-4505	damage	event[225]	new[225]	_	_
25-29	4506-4508	in	event[225]	new[225]	_	_
25-30	4509-4511	CD	event[225]|abstract|person[227]	new[225]|giv|giv[227]	coref|coref	26-36[239_227]|29-12
25-31	4512-4520	patients	event[225]|person[227]	new[225]|giv[227]	_	_
25-32	4521-4522	.	_	_	_	_

#Text=It has been shown that disruption of epithelial and vascular barriers in the intestine were early events in non-alcoholic steatohepatitis ( NASH ) , and GVB leakage marker could be identified in colonic biopsies in patients with NASH .
26-1	4523-4525	It	abstract	giv	_	_
26-2	4526-4529	has	_	_	_	_
26-3	4530-4534	been	_	_	_	_
26-4	4535-4540	shown	_	_	_	_
26-5	4541-4545	that	_	_	_	_
26-6	4546-4556	disruption	event[229]	new[229]	coref	26-16[232_229]
26-7	4557-4559	of	event[229]	new[229]	_	_
26-8	4560-4570	epithelial	event[229]|abstract[230]	new[229]|new[230]	coref	27-4[243_230]
26-9	4571-4574	and	event[229]|abstract[230]	new[229]|new[230]	_	_
26-10	4575-4583	vascular	event[229]|abstract[230]	new[229]|new[230]	_	_
26-11	4584-4592	barriers	event[229]|abstract[230]	new[229]|new[230]	_	_
26-12	4593-4595	in	event[229]|abstract[230]	new[229]|new[230]	_	_
26-13	4596-4599	the	event[229]|abstract[230]|object[231]	new[229]|new[230]|giv[231]	_	_
26-14	4600-4609	intestine	event[229]|abstract[230]|object[231]	new[229]|new[230]|giv[231]	_	_
26-15	4610-4614	were	_	_	_	_
26-16	4615-4620	early	event[232]	giv[232]	_	_
26-17	4621-4627	events	event[232]	giv[232]	_	_
26-18	4628-4630	in	event[232]	giv[232]	_	_
26-19	4631-4644	non-alcoholic	event[232]|abstract[233]	giv[232]|new[233]	appos	26-22[0_233]
26-20	4645-4660	steatohepatitis	event[232]|abstract[233]	giv[232]|new[233]	_	_
26-21	4661-4662	(	_	_	_	_
26-22	4663-4667	NASH	abstract	giv	coref	26-38
26-23	4668-4669	)	_	_	_	_
26-24	4670-4671	,	_	_	_	_
26-25	4672-4675	and	_	_	_	_
26-26	4676-4679	GVB	abstract|abstract[237]	giv|giv[237]	_	_
26-27	4680-4687	leakage	abstract|abstract[237]	new|giv[237]	_	_
26-28	4688-4694	marker	abstract[237]	giv[237]	_	_
26-29	4695-4700	could	_	_	_	_
26-30	4701-4703	be	_	_	_	_
26-31	4704-4714	identified	_	_	_	_
26-32	4715-4717	in	_	_	_	_
26-33	4718-4725	colonic	abstract[238]	new[238]	_	_
26-34	4726-4734	biopsies	abstract[238]	new[238]	_	_
26-35	4735-4737	in	_	_	_	_
26-36	4738-4746	patients	person[239]	giv[239]	_	_
26-37	4747-4751	with	person[239]	giv[239]	_	_
26-38	4752-4756	NASH	person[239]|abstract	giv[239]|giv	coref	29-19
26-39	4757-4758	.	_	_	_	_

#Text=Of importance , SB epithelial and vascular barriers are FXR-controlled , which opens avenues to clinical trials aimed at investigation of novel FXR-agonists as future therapeutics .
27-1	4759-4761	Of	_	_	_	_
27-2	4762-4772	importance	abstract	new	_	_
27-3	4773-4774	,	_	_	_	_
27-4	4775-4777	SB	abstract|abstract[243]	giv|giv[243]	coref|coref	28-4[249_243]|29-3[255_0]
27-5	4778-4788	epithelial	abstract[243]	giv[243]	_	_
27-6	4789-4792	and	abstract[243]	giv[243]	_	_
27-7	4793-4801	vascular	abstract[243]	giv[243]	_	_
27-8	4802-4810	barriers	abstract[243]	giv[243]	_	_
27-9	4811-4814	are	_	_	_	_
27-10	4815-4829	FXR-controlled	_	_	_	_
27-11	4830-4831	,	_	_	_	_
27-12	4832-4837	which	_	_	_	_
27-13	4838-4843	opens	_	_	_	_
27-14	4844-4851	avenues	abstract	new	_	_
27-15	4852-4854	to	_	_	_	_
27-16	4855-4863	clinical	event[245]	new[245]	_	_
27-17	4864-4870	trials	event[245]	new[245]	_	_
27-18	4871-4876	aimed	event[245]	new[245]	_	_
27-19	4877-4879	at	event[245]	new[245]	_	_
27-20	4880-4893	investigation	event[245]|abstract[246]	new[245]|new[246]	_	_
27-21	4894-4896	of	event[245]|abstract[246]	new[245]|new[246]	_	_
27-22	4897-4902	novel	event[245]|abstract[246]|abstract[247]	new[245]|new[246]|new[247]	_	_
27-23	4903-4915	FXR-agonists	event[245]|abstract[246]|abstract[247]	new[245]|new[246]|new[247]	_	_
27-24	4916-4918	as	event[245]|abstract[246]	new[245]|new[246]	_	_
27-25	4919-4925	future	event[245]|abstract[246]|abstract[248]	new[245]|new[246]|new[248]	_	_
27-26	4926-4938	therapeutics	event[245]|abstract[246]|abstract[248]	new[245]|new[246]|new[248]	_	_
27-27	4939-4940	.	_	_	_	_

#Text=Of interest , intestinal barriers could be monitored in vivo with the aid of confocal laser endomicroscopy ( CLE ) .
28-1	4941-4943	Of	_	_	_	_
28-2	4944-4952	interest	_	_	_	_
28-3	4953-4954	,	_	_	_	_
28-4	4955-4965	intestinal	abstract[249]	giv[249]	coref	31-6[274_249]
28-5	4966-4974	barriers	abstract[249]	giv[249]	_	_
28-6	4975-4980	could	_	_	_	_
28-7	4981-4983	be	_	_	_	_
28-8	4984-4993	monitored	_	_	_	_
28-9	4994-4996	in	_	_	_	_
28-10	4997-5001	vivo	abstract	new	_	_
28-11	5002-5006	with	_	_	_	_
28-12	5007-5010	the	abstract[251]	new[251]	_	_
28-13	5011-5014	aid	abstract[251]	new[251]	_	_
28-14	5015-5017	of	abstract[251]	new[251]	_	_
28-15	5018-5026	confocal	abstract[251]|abstract[253]	new[251]|new[253]	appos	28-19[0_253]
28-16	5027-5032	laser	abstract[251]|object|abstract[253]	new[251]|new|new[253]	_	_
28-17	5033-5047	endomicroscopy	abstract[251]|abstract[253]	new[251]|new[253]	_	_
28-18	5048-5049	(	_	_	_	_
28-19	5050-5053	CLE	abstract	giv	_	_
28-20	5054-5055	)	_	_	_	_
28-21	5056-5057	.	_	_	_	_

#Text=Therefore , the SB is considered a key player in metabolic disease development , including diabetes mellitus and NASH , and other diet-related disorders such as coeliac and non-coeliac enteropathies .
29-1	5058-5067	Therefore	_	_	_	_
29-2	5068-5069	,	_	_	_	_
29-3	5070-5073	the	abstract[255]	giv[255]	coref	31-19[276_255]
29-4	5074-5076	SB	abstract[255]	giv[255]	_	_
29-5	5077-5079	is	_	_	_	_
29-6	5080-5090	considered	_	_	_	_
29-7	5091-5092	a	person[256]	new[256]	_	_
29-8	5093-5096	key	person[256]	new[256]	_	_
29-9	5097-5103	player	person[256]	new[256]	_	_
29-10	5104-5106	in	person[256]	new[256]	_	_
29-11	5107-5116	metabolic	person[256]|abstract[258]	new[256]|new[258]	_	_
29-12	5117-5124	disease	person[256]|abstract|abstract[258]	new[256]|giv|new[258]	coref	31-32[279_0]
29-13	5125-5136	development	person[256]|abstract[258]	new[256]|new[258]	_	_
29-14	5137-5138	,	person[256]|abstract[258]	new[256]|new[258]	_	_
29-15	5139-5148	including	person[256]|abstract[258]	new[256]|new[258]	_	_
29-16	5149-5157	diabetes	person[256]|abstract[258]|abstract[259]	new[256]|new[258]|new[259]	_	_
29-17	5158-5166	mellitus	person[256]|abstract[258]|abstract[259]	new[256]|new[258]|new[259]	_	_
29-18	5167-5170	and	person[256]|abstract[258]	new[256]|new[258]	_	_
29-19	5171-5175	NASH	person[256]|abstract[258]|abstract	new[256]|new[258]|giv	_	_
29-20	5176-5177	,	person[256]|abstract[258]	new[256]|new[258]	_	_
29-21	5178-5181	and	person[256]|abstract[258]	new[256]|new[258]	_	_
29-22	5182-5187	other	person[256]|abstract[258]|abstract[261]	new[256]|new[258]|new[261]	_	_
29-23	5188-5200	diet-related	person[256]|abstract[258]|abstract[261]	new[256]|new[258]|new[261]	_	_
29-24	5201-5210	disorders	person[256]|abstract[258]|abstract[261]	new[256]|new[258]|new[261]	_	_
29-25	5211-5215	such	person[256]|abstract[258]|abstract[261]	new[256]|new[258]|new[261]	_	_
29-26	5216-5218	as	person[256]|abstract[258]|abstract[261]	new[256]|new[258]|new[261]	_	_
29-27	5219-5226	coeliac	person[256]|abstract[258]|abstract[261]|substance[262]	new[256]|new[258]|new[261]|new[262]	_	_
29-28	5227-5230	and	person[256]|abstract[258]|abstract[261]|substance[262]	new[256]|new[258]|new[261]|new[262]	_	_
29-29	5231-5242	non-coeliac	person[256]|abstract[258]|abstract[261]|substance[262]	new[256]|new[258]|new[261]|new[262]	_	_
29-30	5243-5256	enteropathies	person[256]|abstract[258]|abstract[261]|substance[262]	new[256]|new[258]|new[261]|new[262]	_	_
29-31	5257-5258	.	_	_	_	_

#Text=Another major field is drug metabolism and its interaction with small bowel microbiome .
30-1	5259-5266	Another	abstract[263]	new[263]	coref	30-5[265_263]
30-2	5267-5272	major	abstract[263]	new[263]	_	_
30-3	5273-5278	field	abstract[263]	new[263]	_	_
30-4	5279-5281	is	_	_	_	_
30-5	5282-5286	drug	substance|abstract[265]|abstract[266]	new|giv[265]|giv[266]	coref|ana	30-5[266_265]|30-8[0_266]
30-6	5287-5297	metabolism	abstract[265]|abstract[266]	giv[265]|giv[266]	_	_
30-7	5298-5301	and	abstract[266]	giv[266]	_	_
30-8	5302-5305	its	abstract[266]|abstract|abstract[268]	giv[266]|giv|new[268]	_	_
30-9	5306-5317	interaction	abstract[266]|abstract[268]	giv[266]|new[268]	_	_
30-10	5318-5322	with	abstract[266]|abstract[268]	giv[266]|new[268]	_	_
30-11	5323-5328	small	abstract[266]|abstract[268]|object[269]|substance[270]	giv[266]|new[268]|giv[269]|new[270]	_	_
30-12	5329-5334	bowel	abstract[266]|abstract[268]|object[269]|substance[270]	giv[266]|new[268]|giv[269]|new[270]	_	_
30-13	5335-5345	microbiome	abstract[266]|abstract[268]|substance[270]	giv[266]|new[268]|new[270]	_	_
30-14	5346-5347	.	_	_	_	_

#Text=Moreover , the emergence of gut-brain , gut-liver , and gut-blood barriers point towards the important role of the SB in the pathogenesis of previously unthought and GI-unrelated conditions such as neurodegenerative and cardiovascular disease .
31-1	5348-5356	Moreover	_	_	_	_
31-2	5357-5358	,	_	_	_	_
31-3	5359-5362	the	event[271]	new[271]	_	_
31-4	5363-5372	emergence	event[271]	new[271]	_	_
31-5	5373-5375	of	event[271]	new[271]	_	_
31-6	5376-5385	gut-brain	event[271]|object|abstract[274]	new[271]|giv|giv[274]	_	_
31-7	5386-5387	,	event[271]|abstract[274]	new[271]|giv[274]	_	_
31-8	5388-5397	gut-liver	event[271]|place|abstract[274]	new[271]|new|giv[274]	_	_
31-9	5398-5399	,	event[271]|abstract[274]	new[271]|giv[274]	_	_
31-10	5400-5403	and	event[271]|abstract[274]	new[271]|giv[274]	_	_
31-11	5404-5413	gut-blood	event[271]|abstract[274]	new[271]|giv[274]	_	_
31-12	5414-5422	barriers	event[271]|abstract[274]	new[271]|giv[274]	_	_
31-13	5423-5428	point	_	_	_	_
31-14	5429-5436	towards	_	_	_	_
31-15	5437-5440	the	abstract[275]	new[275]	_	_
31-16	5441-5450	important	abstract[275]	new[275]	_	_
31-17	5451-5455	role	abstract[275]	new[275]	_	_
31-18	5456-5458	of	abstract[275]	new[275]	_	_
31-19	5459-5462	the	abstract[275]|abstract[276]	new[275]|giv[276]	coref	32-1[280_276]
31-20	5463-5465	SB	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
31-21	5466-5468	in	_	_	_	_
31-22	5469-5472	the	abstract[277]	new[277]	_	_
31-23	5473-5485	pathogenesis	abstract[277]	new[277]	_	_
31-24	5486-5488	of	abstract[277]	new[277]	_	_
31-25	5489-5499	previously	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-26	5500-5509	unthought	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-27	5510-5513	and	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-28	5514-5526	GI-unrelated	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-29	5527-5537	conditions	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-30	5538-5542	such	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-31	5543-5545	as	abstract[277]|abstract[278]	new[277]|new[278]	_	_
31-32	5546-5563	neurodegenerative	abstract[277]|abstract[278]|abstract[279]	new[277]|new[278]|giv[279]	_	_
31-33	5564-5567	and	abstract[277]|abstract[278]|abstract[279]	new[277]|new[278]|giv[279]	_	_
31-34	5568-5582	cardiovascular	abstract[277]|abstract[278]|abstract[279]	new[277]|new[278]|giv[279]	_	_
31-35	5583-5590	disease	abstract[277]|abstract[278]|abstract[279]	new[277]|new[278]|giv[279]	_	_
31-36	5591-5592	.	_	_	_	_

#Text=The SB remains an organ that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge .
32-1	5593-5596	The	abstract[280]	giv[280]	coref	34-14[289_280]
32-2	5597-5599	SB	abstract[280]	giv[280]	_	_
32-3	5600-5607	remains	_	_	_	_
32-4	5608-5610	an	object[281]	new[281]	_	_
32-5	5611-5616	organ	object[281]	new[281]	_	_
32-6	5617-5621	that	object[281]	new[281]	_	_
32-7	5622-5624	is	object[281]	new[281]	_	_
32-8	5625-5634	difficult	object[281]	new[281]	_	_
32-9	5635-5637	to	object[281]	new[281]	_	_
32-10	5638-5643	fully	object[281]	new[281]	_	_
32-11	5644-5650	access	object[281]	new[281]	_	_
32-12	5651-5654	and	object[281]	new[281]	_	_
32-13	5655-5661	assess	object[281]	new[281]	_	_
32-14	5662-5665	and	_	_	_	_
32-15	5666-5674	accurate	abstract[282]	new[282]	_	_
32-16	5675-5684	diagnosis	abstract[282]	new[282]	_	_
32-17	5685-5690	often	_	_	_	_
32-18	5691-5696	poses	_	_	_	_
32-19	5697-5698	a	abstract[283]	new[283]	_	_
32-20	5699-5707	clinical	abstract[283]	new[283]	_	_
32-21	5708-5717	challenge	abstract[283]	new[283]	_	_
32-22	5718-5719	.	_	_	_	_

#Text=Undoubtedly , the therapeutic potential remains untapped .
33-1	5720-5731	Undoubtedly	_	_	_	_
33-2	5732-5733	,	_	_	_	_
33-3	5734-5737	the	abstract[284]	new[284]	ana	34-3[0_284]
33-4	5738-5749	therapeutic	abstract[284]	new[284]	_	_
33-5	5750-5759	potential	abstract[284]	new[284]	_	_
33-6	5760-5767	remains	_	_	_	_
33-7	5768-5776	untapped	_	_	_	_
33-8	5777-5778	.	_	_	_	_

#Text=Therefore , it is now time to direct more of our interest towards the SB and unravel the interplay between the SB and other GI and non-GI related diseases .
34-1	5779-5788	Therefore	_	_	_	_
34-2	5789-5790	,	_	_	_	_
34-3	5791-5793	it	abstract	giv	_	_
34-4	5794-5796	is	_	_	_	_
34-5	5797-5800	now	event[286]	new[286]	_	_
34-6	5801-5805	time	event[286]	new[286]	_	_
34-7	5806-5808	to	_	_	_	_
34-8	5809-5815	direct	_	_	_	_
34-9	5816-5820	more	_	_	_	_
34-10	5821-5823	of	_	_	_	_
34-11	5824-5827	our	person|abstract[288]	acc|new[288]	_	_
34-12	5828-5836	interest	abstract[288]	new[288]	_	_
34-13	5837-5844	towards	_	_	_	_
34-14	5845-5848	the	abstract[289]	giv[289]	coref	34-21[291_289]
34-15	5849-5851	SB	abstract[289]	giv[289]	_	_
34-16	5852-5855	and	_	_	_	_
34-17	5856-5863	unravel	_	_	_	_
34-18	5864-5867	the	abstract[290]	new[290]	_	_
34-19	5868-5877	interplay	abstract[290]	new[290]	_	_
34-20	5878-5885	between	abstract[290]	new[290]	_	_
34-21	5886-5889	the	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
34-22	5890-5892	SB	abstract[290]|abstract[291]	new[290]|giv[291]	_	_
34-23	5893-5896	and	_	_	_	_
34-24	5897-5902	other	abstract[293]	giv[293]	_	_
34-25	5903-5905	GI	abstract|abstract[293]	new|giv[293]	_	_
34-26	5906-5909	and	abstract[293]	giv[293]	_	_
34-27	5910-5916	non-GI	abstract[293]	giv[293]	_	_
34-28	5917-5924	related	abstract[293]	giv[293]	_	_
34-29	5925-5933	diseases	abstract[293]	giv[293]	_	_
34-30	5934-5935	.	_	_	_	_
